| Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|---|---|---|---|---|---|---|
Revenues: | |||||||
Product net sales | |||||||
7,126 | 6,197 | 5,549 | 5,144 | 4,819 | 4,447 | 4,339 | 3,879 |
Other revenues | |||||||
111 | 102 | 97 | 72 | 99 | 56 | 63 | 59 |
Total revenues | |||||||
7,237 | 6,300 | 5,646 | 5,216 | 4,919 | 4,503 | 4,403 | 3,938 |
Operating costs and expenses: | |||||||
Cost of sales (excludes amortization of intangible assets) | |||||||
842 | 795 | 751 | 718 | 722 | 750 | 761 | 673 |
Selling, general and administrative | |||||||
2,837 | 2,519 | 2,193 | 2,158 | 2,017 | 1,921 | 1,856 | 1,680 |
Research and development | |||||||
1,191 | 1,042 | 977 | 871 | 804 | 706 | 797 | 718 |
Amortization of intangible assets | |||||||
112 | 116 | 90 | 86 | 138 | 146 | 150 | 121 |
Legal settlement | |||||||
- | - | - | - | 609 | 0 | 0 | - |
Impairment of intangible assets and related costs | |||||||
0 | 11 | 22 | 7 | 369 | 0 | 0 | - |
Restructuring charges | |||||||
245 | 5 | 1 | -0 | 0 | 50 | 41 | 26 |
Operating income | |||||||
2,009 | 1,809 | 1,611 | 1,374 | 258 | 928 | 796 | 719 |
Non-operating income (expense): | |||||||
Interest income | |||||||
7 | 6 | 6 | 6 | 7 | 7 | 33 | 65 |
Interest expense | |||||||
69 | 75 | 63 | 71 | 78 | 76 | 85 | 94 |
Gain on investments, net | |||||||
- | - | - | - | - | 24 | 0 | 0 |
Unrealized (loss) gain on derivative instruments, net | |||||||
- | - | - | - | - | - | - | -0 |
Other, net | |||||||
41 | -10 | -23 | -0 | -16 | -34 | 18 | -25 |
Total non-operating income (expense) | |||||||
-20 | -78 | -80 | -65 | -87 | -79 | -33 | -54 |
Earnings from continuing operations before income taxes | |||||||
1,989 | 1,730 | 1,531 | 1,309 | 170 | 848 | 762 | 664 |
Provision for income taxes | |||||||
456 | 458 | 430 | 359 | 165 | 224 | 197 | 177 |
Earnings from continuing operations | |||||||
1,532 | 1,272 | 1,100 | 949 | - | - | - | 487 |
Discontinued Operations: | |||||||
Earnings from discontinued operations, net of applicable income tax expense of $6.9 million and $0.5 million for the years ended December 31, 2013 and 2012, respectively | |||||||
0 | 14 | 1 | -11 | - | - | - | -0 |
Loss on sale of discontinued operation, net of applicable income tax expense (benefit) of $1.3 million and $(110.3) million for the years ended December 31, 2014 and 2013, respectively | |||||||
-3 | -297 | 0 | 0 | - | - | - | -1 |
Discontinued operations | |||||||
-3 | -283 | 1 | -11 | - | - | - | -1 |
Net earnings | |||||||
1,528 | 988 | 1,102 | 938 | 4 | 623 | 564 | 485 |
Net earnings attributable to noncontrolling interest | |||||||
4 | 3 | 3 | 3 | 4 | 2 | 1 | 0 |
Net earnings attributable to Allergan, Inc. | |||||||
1,524 | 985 | 1,098 | 934 | 0 | 621 | 563 | 484 |
Earnings per share attributable to Allergan, Inc. stockholders: | |||||||
Basic earnings per share attributable to Allergan, Inc. stockholders: | |||||||
Continuing operations (in dollars per share) | |||||||
5.13 | 4.28 | 3.64 | 3.11 | - | - | - | 1.59 |
Discontinued operations (in dollars per share) | |||||||
-0.01 | -0.96 | 0.00 | -0.04 | - | - | - | 0.00 |
Net basic earnings per share attributable to Allergan, Inc. stockholders (in dollars per share) | |||||||
5.12 | 3.32 | 3.64 | 3.07 | 0.00 | 2.05 | 1.85 | 1.59 |
Diluted earnings per share attributable to Allergan, Inc. stockholders: | |||||||
Continuing operations (in dollars per share) | |||||||
5.03 | 4.20 | 3.57 | 3.05 | - | - | - | 1.58 |
Discontinued operations (in dollars per share) | |||||||
-0.02 | -0.94 | 0.01 | -0.04 | - | - | - | -0.01 |
Net diluted earnings per share attributable to Allergan, Inc. stockholder (in dollars per share) | |||||||
5.01 | 3.26 | 3.58 | 3.01 | 0.00 | 2.03 | 1.84 | 1.57 |